Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Dawnrays Pharmaceutical Holdings Ltd.

TOT BIOPHARM International Co. Ltd.

Shanghai Henlius Biotech, Inc.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Charmacy Pharmaceutical Co., Ltd.

Clover Biopharmaceuticals Ltd.

Hua Medicine Ltd.

Transcenta Holding Ltd.

Abbisko Cayman Ltd.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Fusen Pharmaceutical Co., Ltd.

Why is Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. ?

High Debt company with Weak Long Term Fundamental Strength

High Debt Company with a Debt to Equity ratio (avg) at times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 5.86%, its profits have fallen by -122.9%

Underperformed the market in the last 1 year

The stock has generated a return of 5.86% in the last 1 year, much lower than market (Hang Seng Hong Kong) returns of 27.36%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

5.86%

1.18

45.34%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.28%

EBIT Growth (5y)

-187.22%

EBIT to Interest (avg)

64.58

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

0.49

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

129.33%

Pledged Shares

Institutional Holding

ROCE (avg)

11.48%

ROE (avg)

5.95%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.47

EV to EBIT

0.58

EV to EBITDA

-1.81

EV to Capital Employed

-0.03

EV to Sales

-0.06

PEG Ratio

Dividend Yield

0.90%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1.09%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at HKD 4,820.62 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Interest Coverage Ratio

Highest at 3,086

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit

Highest at HKD 124.85 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 27.65 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

At HKD 105.13 MM has Grown at 58.48%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD 103.6 MM has Grown at 60.63%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Inventory Turnover Ratio

Highest at 2.12%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by 1.47% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at HKD 35.71 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Here's what is not working for Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Cash and Eqv

Lowest at HKD 556.66 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -33.86 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio